First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial - Fürstenau, M; Kater, AP; Robrecht, S (Lancet Oncol, 2024)